Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia

Total Page:16

File Type:pdf, Size:1020Kb

Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia Published OnlineFirst May 13, 2019; DOI: 10.1158/2159-8290.CD-18-1474 RESEARCH ARTICLE Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia Emmalee R. Adelman1,2,3, Hsuan-Ting Huang1,2, Alejandro Roisman1,2, André Olsson4, Antonio Colaprico1,2, Tingting Qin5, R. Coleman Lindsley6, Rafael Bejar7, Nathan Salomonis8, H. Leighton Grimes4, and Maria E. Figueroa1,2 Downloaded from cancerdiscovery.aacrjournals.org on October 5, 2021. © 2019 American Association for Cancer Research. Published OnlineFirst May 13, 2019; DOI: 10.1158/2159-8290.CD-18-1474 ABSTRACT Aging is associated with functional decline of hematopoietic stem cells (HSC) as well as an increased risk of myeloid malignancies. We performed an integrative characterization of epigenomic and transcriptomic changes, including single-cell RNA sequencing, dur- ing normal human aging. Lineage−CD34+CD38− cells [HSC-enriched (HSCe)] undergo age-associated epigenetic reprogramming consisting of redistribution of DNA methylation and reductions in H3K27ac, H3K4me1, and H3K4me3. This reprogramming of aged HSCe globally targets developmental and can- cer pathways that are comparably altered in acute myeloid leukemia (AML) of all ages, encompassing loss of 4,646 active enhancers, 3,091 bivalent promoters, and deregulation of several epigenetic modi- fiers and key hematopoietic transcription factors, such as KLF6, BCL6, and RUNX3. Notably,in vitro downregulation of KLF6 results in impaired differentiation, increased colony-forming potential, and changes in expression that recapitulate aging and leukemia signatures. Thus, age-associated epigenetic reprogramming may form a predisposing condition for the development of age-related AML. SIGNIFICANCE: AML, which is more frequent in the elderly, is characterized by epigenetic deregulation. We demonstrate that epigenetic reprogramming of human HSCs occurs with age, affecting cancer and developmental pathways. Downregulation of genes epigenetically altered with age leads to impairment in differentiation and partially recapitulates aging phenotypes. INTRODUCTION epigenetic modifiersDNMT3A, TET2, and ASXL1, as well as in proteins involved in alternative splicing such as SF3B1 The world’s population is aging. By 2050, more than 1.5 and SRSF2. However, although patients carrying these muta- billion people, or roughly double the current percentage tions experience an overall increased likelihood of develop- of the population, will be 65 years of age or older (1). This ing hematologic malignancies, this occurs at a rate of only change in demographics will require a better understanding 0.5% to 1% per year and does not affect every carrier (6–10). of aging-associated features and medical challenges, includ- Moreover, not all age-related myeloid malignancies occur in ing the higher incidence of cancer. At the hematopoietic level, the context of CHIP mutations. Thus, additional events must aging is associated with an increased rate of isolated cytope- be necessary to initiate malignant transformation in healthy nias of unknown significance, loss of adaptive immunity, and individuals. an increased predisposition to develop myeloid malignancies Aged hematopoietic stem cells (HSC) display decreased such as myelodysplastic syndromes (MDS) and acute myeloid self-renewal, reduced homing ability, and an ultimate mye- leukemia (AML; refs. 2–5). In addition, aging correlates with loid differentiation bias due to reduced lymphoid poten- an increased incidence of clonal hematopoiesis of indeter- tial (11–15). This loss of function is due in part to altered minate potential (CHIP) with frequent mutations in the DNA damage response and accumulation of DNA damage, increased reactive oxygen species (ROS), and modifications in WNT signaling (16–21). Notably, reprogramming of HSCs 1Department of Human Genetics, University of Miami Miller School of through a pluripotent intermediate partially rejuvenates aged Medicine, Miami, Florida. 2Sylvester Comprehensive Cancer Center, Uni- murine HSCs, suggesting that epigenetic changes with age versity of Miami Miller School of Medicine, Miami, Florida. 3Department contribute to impaired HSC function (22). of Pathology, University of Michigan Medical School, Ann Arbor, Michigan. In line with this, changes in the epigenome have been 4Division of Immunobiology and Center for Systems Immunology, Cincin- nati Children’s Hospital Medical Center, Cincinnati, Ohio. 5Department reported with normal aging. Aged murine HSCs display of Computational Medicine and Bioinformatics, University of Michigan regional gains in DNA methylation as well as an increase Medical School, Ann Arbor, Michigan. 6Department of Medical Oncology, in the number and breadth of H3K4me3 peaks, suggest- Division of Hematological Malignancies, Dana-Farber Cancer Institute, ing that epigenetic shifts with age may contribute to HSC Boston, Massachusetts. 7Division of Hematology and Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, California. loss of function (23, 24). In human hematopoietic progeni- 8Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical tors, global changes in histone modification levels have been Center, Cincinnati, Ohio. reported (25), but detailed studies into chromatin profiles of Note: Supplementary data for this article are available at Cancer Discovery aged human HSCs are still lacking. Likewise, although DNA Online (http://cancerdiscovery.aacrjournals.org/). methylation has been profiled in human specimens, these H.-T. Huang and A. Roisman contributed equally to this article. studies utilized either peripheral blood, bulk mononuclear Corresponding Author: Maria E. Figueroa, University of Miami Miller cells (MNC), or unfractionated CD34+ bone marrow cells (26, School of Medicine, 1501 NW 10th Avenue, BRB 723, Miami, FL 33136. 27). Thus, it is as yet unknown if the age-related epigenetic Phone: 305-243-7333; Fax: 646-422-2288; E-mail: [email protected] differences observed in aged murine HSCs are representative Cancer Discov 2019;9:1–22 of those that occur with human HSC aging, or whether these doi: 10.1158/2159-8290.CD-18-1474 epigenetic changes contribute to the increased risk of malig- ©2019 American Association for Cancer Research. nant transformation. AUGUST 2019 CANCER DISCOVERY | OF2 Downloaded from cancerdiscovery.aacrjournals.org on October 5, 2021. © 2019 American Association for Cancer Research. Published OnlineFirst May 13, 2019; DOI: 10.1158/2159-8290.CD-18-1474 RESEARCH ARTICLE Adelman et al. In recent years, there has been increasing evidence for the massively parallel sequencing (micro ChIP-seq), we deter- role of deregulated enhancers and other regulatory elements mined the genome-wide distribution of H3K4me1, H3K27ac, in hematologic malignancies (28–32). Thus, given the epige- H3K4me3, and H3K27me3, on 4 to 7 independent donors netic changes observed with mouse HSC aging, we hypoth- per age, per mark. Differential peak calling analysis for esized that aging of human HSCs is associated with changes each of these four histone marks across the two age groups in the epigenetic landscape that likely affect enhancers and revealed that aging is associated with significant reductions other regulatory elements, and contribute to aged HSC loss in H3K4me1, H3K27ac, and H3K4me3, affecting 14,077 (11% of function and increased risk of malignant transformation. of all young peaks), 10,512 (24%), and 18,195 (31%) peaks, respectively (log10 likelihood ratio > 3, absolute fold-change RESULTS ≥ 1.5). Notably, relatively few regions had an increase in signal intensity of H3K4me1 (n = 229 peaks), H3K4me3 Aged HSCs Display Systematic Changes in Histone (n = 17 peaks), or H3K27ac (n = 35 peaks) with age (Fig. 1A; and Cytosine Modifications Supplementary Fig. S2A and S2B). Importantly, although We hypothesized that epigenetic changes in human HSCs age-related changes in H3K27ac, H3K4me3, and H3K4me1 with aging may underlie the age-related functional decline were distributed across the genome, these changes were not observed in these cells. Therefore, to perform a comprehensive random, but were instead focalized at specific areas of the characterization of the epigenetic and transcriptional land- genome that were reproducibly affected across the differ- scape of these cells, bone marrow MNCs were collected from a ent donors. In contrast, H3K27me3 displayed only 1,564 total of 41 young (18–30 years old) and 55 aged (65–75 years H3K27me3 peaks changed with aging, consisting of both old) healthy donors. We first evaluated the frequencies of the gains (25% of differential peaks) and losses (75% of differen- HSC-enriched lineage-negative (Lin−) CD34+ CD38− (herein tial peaks) of H3K27me3. However, despite fewer H3K27me3 HSCe) fraction, granulocyte–monocyte progenitors (GMP; peaks being affected with aging, these peaks displayed the Lin−CD34+CD38+CD45.RA+CD123+), common myeloid pro- greatest magnitude of change in signal intensity (Supplemen- genitors (CMP; Lin−CD34+CD38+CD45.RA−CD123+), and meg- tary Fig. S2A and S2B; Supplementary Table S2). akaryocyte–erythrocyte progenitors (MEP; Lin−CD34+CD38+ To confirm the robustness of these observations and deter- CD45.RA−CD123−) in our cohort. As shown previously, we mine the false discovery rate (FDR) for our approach, we observed an increase in HSCe frequency with age (P = 1.59e-5) performed 100-fold permutation analysis of young and aged as well as a decrease in the frequency of GMP with
Recommended publications
  • Dedifferentiation by Adenovirus E1A Due to Inactivation of Hippo Pathway Effectors YAP and TAZ
    Downloaded from genesdev.cshlp.org on October 3, 2021 - Published by Cold Spring Harbor Laboratory Press Dedifferentiation by adenovirus E1A due to inactivation of Hippo pathway effectors YAP and TAZ Nathan R. Zemke, Dawei Gou, and Arnold J. Berk Molecular Biology Institute, University of California at Los Angeles, Los Angeles, California 90095, USA Adenovirus transformed cells have a dedifferentiated phenotype. Eliminating E1A in transformed human embryonic kidney cells derepressed ∼2600 genes, generating a gene expression profile closely resembling mesenchymal stem cells (MSCs). This was associated with a dramatic change in cell morphology from one with scant cytoplasm and a globular nucleus to one with increased cytoplasm, extensive actin stress fibers, and actomyosin-dependent flat- tening against the substratum. E1A-induced hypoacetylation at histone H3 Lys27 and Lys18 (H3K27/18) was reversed. Most of the increase in H3K27/18ac was in enhancers near TEAD transcription factors bound by Hippo signaling-regulated coactivators YAP and TAZ. E1A causes YAP/TAZ cytoplasmic sequestration. After eliminating E1A, YAP/TAZ were transported into nuclei, where they associated with poised enhancers with DNA-bound TEAD4 and H3K4me1. This activation of YAP/TAZ required RHO family GTPase signaling and caused histone acetylation by p300/CBP, chromatin remodeling, and cohesin loading to establish MSC-associated enhancers and then superenhancers. Consistent results were also observed in primary rat embryo kidney cells, human fibroblasts, and human respiratory tract epithelial cells. These results together with earlier studies suggest that YAP/TAZ function in a developmental checkpoint controlled by signaling from the actin cytoskeleton that prevents differ- entiation of a progenitor cell until it is in the correct cellular and tissue environment.
    [Show full text]
  • Functional Roles of Bromodomain Proteins in Cancer
    cancers Review Functional Roles of Bromodomain Proteins in Cancer Samuel P. Boyson 1,2, Cong Gao 3, Kathleen Quinn 2,3, Joseph Boyd 3, Hana Paculova 3 , Seth Frietze 3,4,* and Karen C. Glass 1,2,4,* 1 Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, VT 05446, USA; [email protected] 2 Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA; [email protected] 3 Department of Biomedical and Health Sciences, University of Vermont, Burlington, VT 05405, USA; [email protected] (C.G.); [email protected] (J.B.); [email protected] (H.P.) 4 University of Vermont Cancer Center, Burlington, VT 05405, USA * Correspondence: [email protected] (S.F.); [email protected] (K.C.G.) Simple Summary: This review provides an in depth analysis of the role of bromodomain-containing proteins in cancer development. As readers of acetylated lysine on nucleosomal histones, bromod- omain proteins are poised to activate gene expression, and often promote cancer progression. We examined changes in gene expression patterns that are observed in bromodomain-containing proteins and associated with specific cancer types. We also mapped the protein–protein interaction network for the human bromodomain-containing proteins, discuss the cellular roles of these epigenetic regu- lators as part of nine different functional groups, and identify bromodomain-specific mechanisms in cancer development. Lastly, we summarize emerging strategies to target bromodomain proteins in cancer therapy, including those that may be essential for overcoming resistance. Overall, this review provides a timely discussion of the different mechanisms of bromodomain-containing pro- Citation: Boyson, S.P.; Gao, C.; teins in cancer, and an updated assessment of their utility as a therapeutic target for a variety of Quinn, K.; Boyd, J.; Paculova, H.; cancer subtypes.
    [Show full text]
  • DNA Methylation Regulates Discrimination of Enhancers From
    Sharifi-Zarchi et al. BMC Genomics (2017) 18:964 DOI 10.1186/s12864-017-4353-7 RESEARCHARTICLE Open Access DNA methylation regulates discrimination of enhancers from promoters through a H3K4me1-H3K4me3 seesaw mechanism Ali Sharifi-Zarchi1,2,3,4†, Daniela Gerovska5†, Kenjiro Adachi6, Mehdi Totonchi3, Hamid Pezeshk7,8, Ryan J. Taft9, Hans R. Schöler6,10, Hamidreza Chitsaz2, Mehdi Sadeghi8,11, Hossein Baharvand3,12* and Marcos J. Araúzo-Bravo5,13,14* Abstract Background: DNA methylation at promoters is largely correlated with inhibition of gene expression. However, the role of DNA methylation at enhancers is not fully understood, although a crosstalk with chromatin marks is expected. Actually, there exist contradictory reports about positive and negative correlations between DNA methylation and H3K4me1, a chromatin hallmark of enhancers. Results: We investigated the relationship between DNA methylation and active chromatin marks through genome- wide correlations, and found anti-correlation between H3K4me1 and H3K4me3 enrichment at low and intermediate DNA methylation loci. We hypothesized “seesaw” dynamics between H3K4me1 and H3K4me3 in the low and intermediate DNA methylation range, in which DNA methylation discriminates between enhancers and promoters, marked by H3K4me1 and H3K4me3, respectively. Low methylated regions are H3K4me3 enriched, while those with intermediate DNA methylation levels are progressively H3K4me1 enriched. Additionally, the enrichment of H3K27ac, distinguishing active from primed enhancers, follows a plateau in the lower range of the intermediate DNA methylation level, corresponding to active enhancers, and decreases linearly in the higher range of the intermediate DNA methylation. Thus, the decrease of the DNA methylation switches smoothly the state of the enhancers from a primed to an active state.
    [Show full text]
  • Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin
    cells Review Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin Agnieszka Bochy ´nska,Juliane Lüscher-Firzlaff and Bernhard Lüscher * ID Institute of Biochemistry and Molecular Biology, Medical School, RWTH Aachen University, Pauwelsstrasse 30, 52057 Aachen, Germany; [email protected] (A.B.); jluescher-fi[email protected] (J.L.-F.) * Correspondence: [email protected]; Tel.: +49-241-8088850; Fax: +49-241-8082427 Received: 18 January 2018; Accepted: 27 February 2018; Published: 2 March 2018 Abstract: Regulation of gene expression is achieved by sequence-specific transcriptional regulators, which convey the information that is contained in the sequence of DNA into RNA polymerase activity. This is achieved by the recruitment of transcriptional co-factors. One of the consequences of co-factor recruitment is the control of specific properties of nucleosomes, the basic units of chromatin, and their protein components, the core histones. The main principles are to regulate the position and the characteristics of nucleosomes. The latter includes modulating the composition of core histones and their variants that are integrated into nucleosomes, and the post-translational modification of these histones referred to as histone marks. One of these marks is the methylation of lysine 4 of the core histone H3 (H3K4). While mono-methylation of H3K4 (H3K4me1) is located preferentially at active enhancers, tri-methylation (H3K4me3) is a mark found at open and potentially active promoters. Thus, H3K4 methylation is typically associated with gene transcription. The class 2 lysine methyltransferases (KMTs) are the main enzymes that methylate H3K4. KMT2 enzymes function in complexes that contain a necessary core complex composed of WDR5, RBBP5, ASH2L, and DPY30, the so-called WRAD complex.
    [Show full text]
  • Genome-Wide Profiling of Active Enhancers in Colorectal Cancer
    Genome-wide proling of active enhancers in colorectal cancer Min Wu ( [email protected] ) Wuhan University https://orcid.org/0000-0003-1372-4764 Qinglan Li Wuhan University Xiang Lin Wuhan University Ya-Li Yu Zhongnan Hospital, Wuhan University Lin Chen Wuhan University Qi-Xin Hu Wuhan University Meng Chen Zhongnan Hospital, Wuhan University Nan Cao Zhongnan Hospital, Wuhan University Chen Zhao Wuhan University Chen-Yu Wang Wuhan University Cheng-Wei Huang Wuhan University Lian-Yun Li Wuhan University Mei Ye Zhongnan Hospital, Wuhan University https://orcid.org/0000-0002-9393-3680 Article Keywords: Colorectal cancer, H3K27ac, Epigenetics, Enhancer, Transcription factors Posted Date: December 10th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-119156/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Genome-wide profiling of active enhancers in colorectal cancer Qing-Lan Li1, #, Xiang Lin1, #, Ya-Li Yu2, #, Lin Chen1, #, Qi-Xin Hu1, Meng Chen2, Nan Cao2, Chen Zhao1, Chen-Yu Wang1, Cheng-Wei Huang1, Lian-Yun Li1, Mei Ye2,*, Min Wu1,* 1 Frontier Science Center for Immunology and Metabolism, Hubei Key Laboratory of Cell Homeostasis, Hubei Key Laboratory of Developmentally Originated Disease, Hubei Key Laboratory of Intestinal and Colorectal Diseases, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, China 2Division of Gastroenterology, Department of Geriatrics, Hubei Clinical Centre & Key Laboratory of Intestinal and Colorectal Diseases, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430072, China #Equal contribution to the study. Contact information *Correspondence should be addressed to Dr. Min Wu, Email: [email protected], Tel: 86-27-68756620, or Dr.
    [Show full text]
  • Overexpression of Androgen Receptor in Prostate Cancer
    ALFONSO URBANUCCI Overexpression of Androgen Receptor in Prostate Cancer ACADEMIC DISSERTATION To be presented, with the permission of the board of Institute of Biomedical Technology of the University of Tampere, for public discussion in the Jarmo Visakorpi Auditorium, of the Arvo Building, Lääkärinkatu 1, Tampere, on January 20th, 2012, at 12 o’clock. UNIVERSITY OF TAMPERE ACADEMIC DISSERTATION University of Tampere, Institute of Biomedical Technology and BioMediTech Tampere University Hospital, Laboratory Centre Graduate Program in Biomedicine and Biotechnology (TGPBB) Finland Supervised by Reviewed by Professor Tapio Visakorpi Docent Auli Karhu University of Tampere University of Helsinki Finland Finland Docent Noora Kotaja University of Turku Finland Copyright ©2012 Tampere University Press and the author Distribution Tel. +358 40 190 9800 Bookshop TAJU Fax +358 3 3551 7685 P.O. Box 617 [email protected] 33014 University of Tampere www.uta.fi/taju Finland http://granum.uta.fi Cover design by Mikko Reinikka Acta Universitatis Tamperensis 1693 Acta Electronica Universitatis Tamperensis 1159 ISBN 978-951-44-8685-2 (print) ISBN 978-951-44-8686-9 (pdf) ISSN-L 1455-1616 ISSN 1456-954X ISSN 1455-1616 http://acta.uta.fi Tampereen Yliopistopaino Oy – Juvenes Print Tampere 2012 CONTENTS ABBREVIATIONS ..................................................................................................... 5 ABSTRACT ................................................................................................................ 7 SINTESI .....................................................................................................................
    [Show full text]
  • Androgen Receptor Interacting Proteins and Coregulators Table
    ANDROGEN RECEPTOR INTERACTING PROTEINS AND COREGULATORS TABLE Compiled by: Lenore K. Beitel, Ph.D. Lady Davis Institute for Medical Research 3755 Cote Ste Catherine Rd, Montreal, Quebec H3T 1E2 Canada Telephone: 514-340-8260 Fax: 514-340-7502 E-Mail: [email protected] Internet: http://androgendb.mcgill.ca Date of this version: 2010-08-03 (includes articles published as of 2009-12-31) Table Legend: Gene: Official symbol with hyperlink to NCBI Entrez Gene entry Protein: Protein name Preferred Name: NCBI Entrez Gene preferred name and alternate names Function: General protein function, categorized as in Heemers HV and Tindall DJ. Endocrine Reviews 28: 778-808, 2007. Coregulator: CoA, coactivator; coR, corepressor; -, not reported/no effect Interactn: Type of interaction. Direct, interacts directly with androgen receptor (AR); indirect, indirect interaction; -, not reported Domain: Interacts with specified AR domain. FL-AR, full-length AR; NTD, N-terminal domain; DBD, DNA-binding domain; h, hinge; LBD, ligand-binding domain; C-term, C-terminal; -, not reported References: Selected references with hyperlink to PubMed abstract. Note: Due to space limitations, all references for each AR-interacting protein/coregulator could not be cited. The reader is advised to consult PubMed for additional references. Also known as: Alternate gene names Gene Protein Preferred Name Function Coregulator Interactn Domain References Also known as AATF AATF/Che-1 apoptosis cell cycle coA direct FL-AR Leister P et al. Signal Transduction 3:17-25, 2003 DED; CHE1; antagonizing regulator Burgdorf S et al. J Biol Chem 279:17524-17534, 2004 CHE-1; AATF transcription factor ACTB actin, beta actin, cytoplasmic 1; cytoskeletal coA - - Ting HJ et al.
    [Show full text]
  • Recognition of Histone Acetylation by the GAS41 YEATS Domain Promotes H2A.Z Deposition in Non-Small Cell Lung Cancer
    Downloaded from genesdev.cshlp.org on October 5, 2021 - Published by Cold Spring Harbor Laboratory Press Recognition of histone acetylation by the GAS41 YEATS domain promotes H2A.Z deposition in non-small cell lung cancer Chih-Chao Hsu,1,2,8 Jiejun Shi,3,8 Chao Yuan,1,2,7,8 Dan Zhao,4,5,8 Shiming Jiang,1,2 Jie Lyu,3 Xiaolu Wang,1,2 Haitao Li,4,5 Hong Wen,1,2 Wei Li,3 and Xiaobing Shi1,2,6 1Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; 2Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; 3Dan L. Duncan Cancer Center, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA; 4MOE Key Laboratory of Protein Sciences, Beijing Advanced Innovation Center for Structural Biology, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China; 5Tsinghua-Peking Joint Center for Life Sciences, Tsinghua University, Beijing 100084, China; 6Genetics and Epigenetics Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas 77030, USA Histone acetylation is associated with active transcription in eukaryotic cells. It helps to open up the chromatin by neutralizing the positive charge of histone lysine residues and providing binding platforms for “reader” proteins. The bromodomain (BRD) has long been thought to be the sole protein module that recognizes acetylated histones. Re- cently, we identified the YEATS domain of AF9 (ALL1 fused gene from chromosome 9) as a novel acetyl-lysine- binding module and showed that the ENL (eleven-nineteen leukemia) YEATS domain is an essential acetyl-histone reader in acute myeloid leukemias.
    [Show full text]
  • Rabbit Anti-Phospho-MCM2-SL18262R-FITC
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-phospho-MCM2 SL18262R-FITC Product Name: Anti-phospho-MCM2 (Ser27)/FITC Chinese Name: FITC标记的磷酸化MCM2蛋白抗体 MCM4 (phospho S27); MCM2(phospho-Ser27); MCM2(phospho Ser27); MCM2 (phospho S27); p-MCM2(Ser27); p-MCM2(S27); MCM2 (phospho S27); p-MCM2 (phospho S27); BM28; CCNL 1; CCNL1; CDC like 1; CDC like-1; cdc19; CDCL 1; CDCL1; Cell devision cycle like 1; Cyclin like 1; cyclin like-1; D3S3194; DNA replication licensing factor MCM2; KIAA0030; MCM 2; MCM2; MCM2 minichromosome maintenance deficient 2 mitotin; MCM2 minichromosome Alias: maintenance deficient 2 mitotin (S. cerevisiae); MCM2 minichromosome maintenance deficient 2, mitotin; MCM2_HUMAN; MCM2_MOUSE; MGC10606; Minichromosome maintenance complex component 2; Minichromosome maintenance deficient 2 (mitotin); Minichromosome maintenance deficient 2 mitotin; Minichromosome maintenance protein 2; Minichromosome maintenance protein 2 homolog; Mitotin; Nuclear protein BM28; OTTHUMP00000216047; OTTHUMP00000216050. Organism Species: Rabbit Clonality: Polyclonalwww.sunlongbiotech.com React Species: Human,Mouse,Rat,Dog,Pig,Rabbit, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 101kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: phosphopeptide derived from human MCM2 around the phosphorylation site of Ser27 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Storage: Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C.
    [Show full text]
  • Anti-Geminin Antibody (Clone 1A8) Mouse Anti Human Monoclonal Antibody Catalog # ALS17716
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Anti-Geminin Antibody (clone 1A8) Mouse Anti Human Monoclonal Antibody Catalog # ALS17716 Specification Anti-Geminin Antibody (clone 1A8) - Product Information Application WB, IHC-P, IF, E Primary Accession O75496 Predicted Human Host Mouse Clonality Monoclonal Isotype IgG1,k Calculated MW 23565 Anti-Geminin Antibody (clone 1A8) - Additional Information Gene ID 51053 Alias Symbol GMNN Other Names GMNN, Geminin Target/Specificity Human Geminin Reconstitution & Storage Protein A purified Precautions Anti-Geminin Antibody (clone 1A8) is for research use only and not for use in diagnostic or therapeutic procedures. Anti-Geminin Antibody (clone 1A8) - Protein Information Name GMNN Function Inhibits DNA replication by preventing the incorporation of MCM complex into pre-replication complex (pre-RC) (PubMed:<a href="http://www.uniprot.org/c itations/9635433" target="_blank">9635433</a>, PubMed:<a href="http://www.uniprot.org/ci tations/14993212" target="_blank">14993212</a>, Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 PubMed:<a href="http://www.uniprot.org/ci tations/20129055" target="_blank">20129055</a>, PubMed:<a href="http://www.uniprot.org/ci tations/24064211" target="_blank">24064211</a>). It is degraded during the mitotic phase of the cell cycle (PubMed:<a href="http://www.uni prot.org/citations/9635433" target="_blank">9635433</a>, PubMed:<a href="http://www.uniprot.org/ci tations/14993212" target="_blank">14993212</a>, PubMed:<a href="http://www.uniprot.org/ci tations/24064211" target="_blank">24064211</a>).
    [Show full text]
  • H3K27 Acetylation and Gene Expression Analysis Reveals Differences in Placental Chromatin Activity in Fetal Growth Restriction N
    Paauw et al. Clinical Epigenetics (2018) 10:85 https://doi.org/10.1186/s13148-018-0508-x RESEARCH Open Access H3K27 acetylation and gene expression analysis reveals differences in placental chromatin activity in fetal growth restriction N. D. Paauw1,6*, A. T. Lely1, J. A. Joles2, A. Franx1, P. G. Nikkels3, M. Mokry4 and B. B. van Rijn1,5,6* Abstract Background: Posttranslational modification of histone tails such as histone 3 lysine 27 acetylation (H3K27ac) is tightly coupled to epigenetic regulation of gene expression. To explore whether this is involved in placenta pathology, we probed genome-wide H3K27ac occupancy by chromatin immunoprecipitation sequencing (ChIP- seq) in healthy placentas and placentas from pathological pregnancies with fetal growth restriction (FGR). Furthermore, we related specific acetylation profiles of FGR placentas to gene expression changes. Results: Analysis of H3K27ac occupancy in FGR compared to healthy placentas showed 970 differentially acetylated regions distributed throughout the genome. Principal component analysis and hierarchical clustering revealed complete segregation of the FGR and control group. Next, we identified 569 upregulated genes and 521 downregulated genes in FGR placentas by RNA sequencing. Differential gene transcription largely corresponded to expected direction based on H3K27ac status. Pathway analysis on upregulated transcripts originating from hyperacetylated sites revealed genes related to the HIF-1-alpha transcription factor network and several other genes with known involvement in placental pathology (LEP, FLT1, HK2, ENG, FOS). Downregulated transcripts in the vicinity of hypoacetylated sites were related to the immune system and growth hormone receptor signaling. Additionally, we found enrichment of 141 transcription factor binding motifs within differentially acetylated regions.
    [Show full text]
  • Enhancer Priming by H3K4 Methylation Safeguards Germline Competence
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.07.192427; this version posted July 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Title: Enhancer priming by H3K4 methylation safeguards germline competence 1* 1 1,2 Authors: Tore Bleckwehl ​ ,​ Kaitlin Schaaf ,​ Giuliano Crispatzu ,​ Patricia ​ ​ ​ ​ 1,3 1,4 5 5 Respuela ,​ Michaela Bartusel ,​ Laura Benson ,​ Stephen J. Clark ,​ Kristel M. ​ ​ ​ ​ 6 7 1,8 7,9 Dorighi ,​ Antonio Barral ,​ Magdalena Laugsch ,​ Miguel Manzanares ,​ Joanna ​ ​ ​ ​ 6,10,11 5,12,13 1,3,14* Wysocka ,​ Wolf Reik ,​ Álvaro Rada-Iglesias ​ ​ ​ ​ ​ ​ Affiliations: 1 Center for Molecular Medicine Cologne (CMMC), University of Cologne, Germany. 2 Department of Internal Medicine 2, University Hospital Cologne. 3 Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), CSIC/University of Cantabria, Spain. 4 Department of Biology, Massachusetts Institute of Technology, USA. 5 Epigenetics Programme, Babraham Institute, Cambridge CB22 3AT, UK. 6 Department of Chemical and Systems Biology, Stanford University School of Medicine, USA. 7 Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain. 8 Institute of Human Genetics, Heidelberg University Hospital, Germany. 9 Centro de Biología Molecular Severo Ochoa (CBMSO), CSIC-UAM, Spain. 10 Department of Developmental Biology, Stanford University School of Medicine, USA. 11 Howard Hughes Medical Institute, Stanford University School of Medicine, USA. 12 Centre for Trophoblast Research, University of Cambridge, CB2 3EG, UK 13 Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK.
    [Show full text]